Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT03987074 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Steatohepatitis

Interventions

DRUG: Semaglutide
DRUG: Firsocostat
DRUG: Cilofexor

Sponsor

Gilead Sciences

Collaborators

[object Object]